Open-Label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV.
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2014
At a glance
- Drugs IC 41 (Primary) ; Imiquimod
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Valneva
- 05 Sep 2008 Status changed from active, no longer recruiting to completed.
- 03 Sep 2008 Six month follow-up results reported in an Intercell media release.
- 06 Feb 2008 Primary endpoint met, according to Intercell media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History